Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Equivalents (2016 - 2025)

Tg Therapeutics has reported Cash & Equivalents over the past 10 years, most recently at $79.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $79.1 million for Q4 2025, up 21233.69% from a year ago — trailing twelve months through Dec 2025 was $79.1 million (up 21233.69% YoY), and the annual figure for FY2025 was $79.1 million, up 21233.69%.
  • Cash & Equivalents for Q4 2025 was $79.1 million at Tg Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TGTX hit a ceiling of $471.5 million in Q1 2021 and a floor of $371000.0 in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $119.5 million (2022), compared with a mean of $157.1 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 99.6% in 2024 and later skyrocketed 21233.69% in 2025.
  • Tg Therapeutics' Cash & Equivalents stood at $298.9 million in 2021, then tumbled by 65.77% to $102.3 million in 2022, then dropped by 9.16% to $92.9 million in 2023, then crashed by 99.6% to $371000.0 in 2024, then skyrocketed by 21233.69% to $79.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $79.1 million (Q4 2025), $1.8 million (Q3 2025), and $129.1 million (Q2 2025) per Business Quant data.